Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial

OBJECTIVE: To assess the incremental cost and cost-effectiveness of continuous and discontinuous regimens of bevacizumab (Avastin) and ranibizumab (Lucentis) for neovascular age-related macular degeneration (nAMD) from a UK National Health Service (NHS) perspective. DESIGN: A within-trial cost-utili...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Dakin, Helen A, Wordsworth, Sarah, Rogers, Chris A, Abangma, Giselle, Raftery, James, Harding, Simon P, Lotery, Andrew J, Downes, Susan M, Chakravarthy, Usha, Reeves, Barnaby C
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2014
Teme:
Health Economics
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4120317/
https://ncbi.nlm.nih.gov/pubmed/25079928
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2014-005094
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items